A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

• Maximum Tolerated Dose (MTD) and/or the recommended dose (RD) for dose expansion of ALT-801 in combination with cisplatin and gemcitabine or ALT-801 in combination with gemcitabine alone [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
• Safety Profile [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
  Number and severity of treatment related AEs that occur or worsen after the first dose of study treatment
• Clinical Benefit [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  Number of participants with an objective response, which includes, a complete response,a partial response or a stable disease

• Maximum Tolerated Dose (MTD) of ALT-801 in combination with cisplatin and gemcitabine [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
• Safety Profile [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
  Number and severity of treatment related AEs that occur or worsen after the first dose of study treatment
• Clinical Benefit [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  Number of participants with an objective response, which includes, a complete response,a partial response or a stable disease

• Progression Free Survival [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  Number of participants with, 6-month, 9-month, 12-month, 18-month, 24-month, 30-month, or 36-month progression-free survival.
• Overall survival [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  Number of participants with 6-month, 9-month, 12-month, 18-month, 24-month, 30-month or 36-month overall survival
• Pharmacokinetics and immunogenicity [ Time Frame: 9 weeks ] [ Designated as safety issue: No ]

  Area under the plasma concentration-time curve from time zero to infinity (AUC) and the half-life of ALT-801 for patients enrolled up to the stage 1 expansion.

  Measures of anti-ALT-801 and IL-2 neutralizing antibodies.

• Tumor Typing [ Time Frame: 1 month ] [ Designated as safety issue: No ]
  Assess the relationship between the tumor presentation of HLA-A*0201/p53 aa 264-272 complexes and the safety and clinical benefits of study treatment

• Progression Free Survival [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  Number of participants with, 6-month, 9-month, 12-month, 18-month, 24-month, 30-month, or 36-month progression-free survival.
• Overall survival [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  Number of participants with 6-month, 9-month, 12-month, 18-month, 24-month, 30-month or 36-month overall survival
• Pharmacokinetics and immunogenicity [ Time Frame: 9 weeks ] [ Designated as safety issue: No ]

  Area under the plasma concentration-time curve from time zero to infinity (AUC) and the half-life of ALT-801.

  Measures of anti-ALT-801 and IL-2 neutralizing antibodies.

This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 in a biochemotherapy regimen either containing cisplatin and gemcitabine or containing gemcitabine alone in patients who have muscle invasive or metastatic urothelial cancer of bladder, renal pelvis, ureters and urethra. The purpose of this study is to evaluate the safety, determine the maximum tolerated dose (MTD) and the recommended dose (RD), and assess the anti-tumor response of ALT-801 in combination with cisplatin and gemcitabine or ALT-801 in combination with gemcitabine alone. The pharmacokinetic profile of ALT-801 in combination with cisplatin and gemcitabine will also be assessed. The study includes a dose escalation phase (Phase Ib) and a dose expansion phase (Phase II). Phase II has two treatment groups, Expansion Group 1 and Expansion Group 2 for platinum-refractory patients as defined in the protocol. The Group 1 expansion will be a two-stage expansion. Patients will enroll to Expansion Group 2 after stage 1 of the Group 1 expansion is complete.

Bladder cancer is the fourth most common malignancy in men and the ninth most common in women in the US, with an estimated 68,810 new cases and 14,070 deaths for the year 2008. Approximately 90% to 95% of newly diagnosed patients are with transitional cell carcinomas (TCC). Approximately 20% to 25% contain advanced (muscle invasive or metastatic) disease. Muscle invasive bladder cancer is life threatening. Clinical trials have demonstrated that TCC is a chemotherapy-sensitive malignancy. Most current cancer treatment strategies involve the use of chemotherapeutic or biological drugs that have a low therapeutic ratio. The limitations are a consequence of effects of the therapeutic drug on normal tissues. One approach to control systemic exposure effects is to target the drug itself into the site of the tumor. For example, antibodies have been developed for use as tumor targeting agents and have had success in the clinic. However, despite the promise of antibody-based immunotherapy, there are limitations with these class of reagents. Even so, immunotherapy remains a promising approach to treat cancer.

One strategy that has received attention is treatment with cytokines such as IL-2 to enhance anti-tumor immunity. IL-2 has stimulatory effects on a number of immune cell types including T and B cells, monocytes, macrophages, lymphokine-activated killer cells (LAK) and natural killer (NK) cells. Based on the ability of IL-2 to provide durable curative anti-tumor responses, systemic administration of IL-2 has been approved to treat patients with metastatic melanoma or renal carcinoma. Unfortunately, the considerable toxicity associated with this treatment makes it difficult to achieve an effective dose at the site of the tumor and limits the population that can be treated. Thus, there is critical need for innovative strategies that enhance the effects of IL-2, to reduce its toxicity without compromising the clinical benefit, and to treat other diagnoses.

The study drug, ALT-801, is a biologic compound of interleukin-2 (IL-2) genetically fused to a humanized soluble T-cell receptor directed against the p53-derived peptides expressed on tumor cells. The p53 protein is one of the most important factors that protects from developing cancer and is also one of the most frequently mutated genes in many cancers, which include muscle-invasive bladder cancer. For any given cancer type, p53 dysfunction generally correlates with poor prognosis versus other the same site-of-origin. In some tumors, p53 mutation and over-expression also is associated with resistance to chemotherapy. This study is to further evaluate whether directing IL-2 activity using ALT-801 to the patient's tumor sites that over-express p53 results in clinical benefits

• Transitional Cell Carcinoma of Bladder
• Urethra Cancer
• Ureter Cancer
• Malignant Tumor of Renal Pelvis

• Drug: Cisplatin
  Intravenous infusion; 3 treatment courses: on day 1 of each course (if given)
• Drug: Gemcitabine
  Intravenous infusion; 3 treatment courses; on day 1 and 8 of each course and day 1 and 15 of the maintenance course (added to maintenance for Phase II)
• Biological: ALT-801
  Intravenous infusion; 3 treatment courses: on day 3, 5, 8, and 12 of each course and Day 1, 3, 15, and 17 of the maintenance course (modified maintenance for Phase II)
  Other Name: c264scTCR-IL2

• Experimental: ALT-801 with Cisplatin and Gemcitabine (Phase Ib and Phase II)
  Interventions:

  • Drug: Cisplatin
  • Drug: Gemcitabine
  • Biological: ALT-801
• Experimental: ALT-801 and Gemcitabine (Phase II only)
  Interventions:

  • Drug: Gemcitabine
  • Biological: ALT-801

ENTRY CRITERIA:

DISEASE CHARATERISTICS:

• Muscle invasive or metastatic urothelial cancer of bladder, ureters, renal pelvis, and urethra
• Histologically or cytologically confirmed with a clinical plan that would potentially include cisplatin plus gemcitabine systemic therapy or with disease refractory to platinum-based therapy (as defined in the protocol).
• Surgically incurable

PRIOR/CONCURRENT THERAPY:

• No concurrent radiotherapy, other chemotherapy, or other immunotherapy
• Must have recovered from side effects of prior treatments
• If prior Proleukin® treatment, must have had a clinical benefit
• No use of other investigational agents within 30 days of start or concurrently

PATIENT CHARACTERISTICS:

Age

• > 18 years

Performance Status

• ECOG 0 or 1

Bone Marrow Reserve

• Absolute neutrophil count (AGC/ANC) ≥ 1,500/uL
• Platelets ≥ 100,000/uL
• Hemoglobin ≥ 10g/dL

Renal Function

• Glomerular Filtration Rate (GFR) > 50mL/min/1.73m^2

  * Refractory to platinum-based therapy: (GFR) ≥40 mL/min/1.73m^2 Hepatic Function

• Total bilirubin ≤ 1.5 X ULN
• AST, ALT, ALP ≤ 2.5 X ULN, or ≤ 5.0 X ULN (if liver metastases exists)
• PT INR ≤ 1.5 X ULN

Cardiovascular

• No congestive heart failure < 6 months
• No unstable angina pectoris < 6 months
• No myocardial infarction < 6 months
• No history of ventricular arrhythmias
• No NYHA Class > II CHF
• Normal cardiac stress test required for subjects who are ≥ 50 years old, or have a history of EKG abnormalities, or have symptoms of cardiac ischemia or arrhythmia
• No uncontrolled hypertension

Pulmonary

• Not receiving chronic medication for asthma
• Normal clinical assessment of pulmonary function

Hematologic

• No evidence of bleeding diathesis or coagulopathy

Other

• Negative serum pregnancy test if female and of childbearing potential
• No women who are pregnant or nursing
• Subjects, both females and males, with reproductive potential must agree to use effective contraceptive measures for the duration of the study
• No known autoimmune disease other than corrected hypothyroidism
• No known prior organ allograft or allogeneic transplantation
• Not HIV positive
• No active systemic infection requiring parenteral antibiotic therapy
• No ongoing systemic steroid therapy required
• No history or evidence of CNS disease (Controlled brain metastases treated with radiation therapy or surgery where the disease has been clinically stable for a period of a least 3 months before screening is allowed)
• No psychiatric illness/social situation
• No other illness that in the opinion of the investigator would exclude the subject from participating in the study
• Must provide informed consent and HIPAA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations